Although transcatheter arrhythmia ablation (TCA) has been performed in children for over two decades, guidelines for routine use of post-ablation transthoracic echocardiography (TTE) are absent. We sought to determine the efficacy of TTE after apparently uneventful TCA procedures in detecting adverse findings and identify predisposing factors. A retrospective review of clinical and procedural data on patients who underwent TCA for supraventricular arrhythmias from 2000 to 2015 was performed. Pre- and post-ablation TTE data were reviewed. All patients were followed at 1 week, 6 and 12 months post-TCA. A repeat TTE was performed at 12 months on patients in whom post-TCA abnormalities were found. Patients were divided into two groups: those with and without adverse TTE findings and comparative analysis between variables was performed. Data on 252 patients, 52% males, mean age 14 ± 3 years were analyzed. New onset or worsening atrioventricular valve regurgitation occurred in 17 (6.7%), a small pericardial effusion in 3 (1.2%) and worsened ventricular function in 2 patients (0.8%). Patients in the complication group had higher mean number of ablations (22.6 ± 15.3 vs. 16.8 ± 9.2, p 0.001) and required longer duration of ablation (sec) (254.6 ± 256.4 vs. 180.9 ± 158.9, p < 0.001). TCA location (including coronary sinus), energy source, arrhythmia substrate, and a trans-septal approach were noncontributory to any adverse findings. Routine post-ablation TTE uncovers asymptomatic self-resolving abnormalities that typically do not require any intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00246-017-1680-z | DOI Listing |
J Med Internet Res
December 2024
School of Automation, Central South University, Changsha, China.
Background: Private-part skin diseases (PPSDs) can cause a patient's stigma, which may hinder the early diagnosis of these diseases. Artificial intelligence (AI) is an effective tool to improve the early diagnosis of PPSDs, especially in preventing the deterioration of skin tumors in private parts such as Paget disease. However, to our knowledge, there is currently no research on using AI to identify PPSDs due to the complex backgrounds of the lesion areas and the challenges in data collection.
View Article and Find Full Text PDFElife
December 2024
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis.
View Article and Find Full Text PDFClin Transl Gastroenterol
December 2024
Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Introduction: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073 val/val ) related to Na v 1.8, a voltage-gated sodium channel preferentially expressed on nociceptors.
View Article and Find Full Text PDFClin J Am Soc Nephrol
October 2024
OptumLabs, Eden Prairie, Minnesota.
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!